modelDalbavancin
Extends from Pharmacolibrary.Drugs.ATC.J.J01XA04.
Information
| name: | Dalbavancin | |
| ATC code: | J01XA04 | route: | intravenous |
| compartments: | 2 | |
| dosage: | 1000 | mg |
| volume of distribution: | 10.2 | L |
| clearance: | 0.05 | L/h |
| other parameters in model implementation | ||
Dalbavancin is a second-generation lipoglycopeptide antibiotic with activity primarily against Gram-positive bacteria, including methicillin-resistant Staphylococcus aureus (MRSA). It is approved for the treatment of acute bacterial skin and skin structure infections (ABSSSI) in adults and is administered as an intravenous infusion.
Pharmacokinetics
Pharmacokinetic parameters are based on data from healthy adult volunteers receiving intravenous dalbavancin. Most studies use a two-compartment model.
References
Carrothers, TJ, et al., & Critchley, I (2020). Dalbavancin Population Pharmacokinetic Modeling and Target Attainment Analysis. Clinical pharmacology in drug development 9(1) 21–31. DOI:10.1002/cpdd.695 PUBMED:https://pubmed.ncbi.nlm.nih.gov/31087630
Turner, NA, et al., & Holland, TL (2022). Dalbavancin as an option for treatment of S. aureus bacteremia (DOTS): study protocol for a phase 2b, multicenter, randomized, open-label clinical trial. Trials 23(1) 407–None. DOI:10.1186/s13063-022-06370-1 PUBMED:https://pubmed.ncbi.nlm.nih.gov/35578360
Colaneri, M, et al., & Seminari, E (2024). Optimizing Antibiotic Therapy for Intravenous Drug Users: A Narrative Review Unraveling Pharmacokinetics/Pharmacodynamics Challenges. European journal of drug metabolism and pharmacokinetics 49(2) 123–129. DOI:10.1007/s13318-024-00882-8 PUBMED:https://pubmed.ncbi.nlm.nih.gov/38332425
Parameters
| Type | Name | Default | Description |
|---|---|---|---|
| Modelica.Units.SI.Mass | weight (from PK_1C) | 75 | patient weight (kg) |
| Modelica.Units.SI.SpecificVolume | VdPerKg (from PK_1C) | 0.9 | Volume of distribution (L/kg) |
| Modelica.Units.SI.MassFraction | F (from PK_1C) | 0.8 | bioavailiability (0-1) |
| Pharmacolibrary.Types.Clearance | Cl (from PK_1C) | 20 | clearance |
| Modelica.Units.SI.Time | adminTime (from PK_1C) | 60 | first administration time (s) |
| Modelica.Units.SI.Time | adminDuration (from PK_1C) | 600 | administration duration (s) |
| Modelica.Units.SI.Time | adminPeriod (from PK_1C) | 8*60*60 | period of administration (default 8 hours)(s) |
| Pharmacolibrary.Types.Mass | adminMass (from PK_1C) | 1000 | administration mass (mg) |
| Integer | adminCount (from PK_1C) | 8 | number of dose administered (1) |
| Pharmacolibrary.Types.Volume | Vd (from PK_1C) | VdPerKg*weight | Volume of distribution (m3) |
| Pharmacolibrary.Types.MassConcentration | Cmin (from PK_1C) | 0.004 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Cmax (from PK_1C) | 0.008 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Ctox_peak (from PK_1C) | 0.012 | toxicity peak level |
| Pharmacolibrary.Types.MassConcentration | Ctox_trough (from PK_1C) | 0.006 | toxicity trough level |
| Pharmacolibrary.Types.Volume | Vdp (from PK_2C) | VdpPerKg*weight | Volume of distribution (m3) |
| Modelica.Units.SI.SpecificVolume | VdpPerKg (from PK_2C) | 0.9 | Volume of distribution peripheral(l/kg) |
| Pharmacolibrary.Types.Clearance | k12 (from PK_2C) | 1 | intercompartmental C-P clearance |
| Pharmacolibrary.Types.Clearance | k21 (from PK_2C) | 1 | intercompartmental P-C clearance |
Connectors
| Type | Name | Default | Description |
|---|---|---|---|
| Types.ConcentrationOutput | C_central (from PK_1C) | ||
| Interfaces.ConcentrationPort_b | centralCPort (from PK_1C) | ||
| Interfaces.ConcentrationPort_b | peripheralCPort (from PK_2C) | ||
| Pharmacolibrary.Types.ConcentrationOutput | C_peripheral1 (from PK_2C) |
Components
| Type | Name | Default | Description |
|---|---|---|---|
| Pharmacokinetic.NoPerfusedTissueCompartment | central (from PK_1C) | ||
| Pharmacokinetic.ClearanceDrivenElimination | elim (from PK_1C) | ||
| Sources.PeriodicDose | periodicDose (from PK_1C) | ||
| Modelica.Units.SI.Time | t1_2 (from PK_1C) | elimination half-life | |
| Pharmacolibrary.Pharmacokinetic.TransferFirstOrderNonSym | transfer (from PK_2C) | ||
| Pharmacolibrary.Pharmacokinetic.NoPerfusedTissueCompartment | peripheral (from PK_2C) |
Revisions
- 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)